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Abstract
Patents might incentivize invention but they do not guarantee firms will invest in projects that
maximize social utility. We model how risk-neutral firms’ ability to obtain substantial private
returns on marginal new technologies causes them to “reach for mediocrity” by investing in
socially-suboptimal projects, even in the presence of competition and new entrants. Focusing
primarily on pharmaceutical innovation, we analyze various policy interventions to solve this
underinvestment problem. In particular, we describe a new approach to patents – a value-based
patent system, which ties patent protection to the underlying invention’s social value – and show
how it incentivizes socially-optimal innovation.
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1 Introduction
In a competitive market, research and development is risky because firms must recover up-front
fixed costs through lower future expenses or increased future sales. Unfortunately, R&D is likely
produced in socially-suboptimal quantities due to the knowledge spillovers it generates and the
potential for competitors to free-ride on originators’ eﬀorts. Accordingly, society subsidizes R&D
through direct subsidies and research grants, tax credits and deductions, rewards, and patents
(Grabowski et al. [2015]; Hemel and Ouellette [2013]; Shavell and Van Ypersele [2001]; Kremer
[1998]).
While many scholars have focused on which innovation policies optimally encourage R&D
spending, there has been less focus on the specific R&D activities these firms pursue. Put
diﬀerently, firms typically have some choice in their R&D investments. Given this choice, are
they picking socially-optimal R&D projects?
Generally, the profit motive should induce firms to choose R&D projects that society values
highly. But as we show in this paper, sometimes firms are excessively conservative compared
to a social planner when selecting investment projects in innovation markets. The problem is
particularly acute in pharmaceuticals, though our argument could also extend to other markets.
The following section provides empirical motivation for the paper and explains why firms
often invest in marginally beneficial or “me-too” drugs, which are often highly profitable despite
providing minimal marginal social benefits. We then present both discrete- and continuous-
choice models that explain how a firm’s return function – what the firm earns as a function of
an underlying invention’s social value – creates a wedge between its incentives and those of the
social planner. We also show how this wedge can persist even with competition and potential
new entrants into the market.
We then assess how various conventional policy interventions – such as changing the drug
approval threshold, awarding prizes, and assessing lump-sum taxes – might address this discon-
nect between social and private incentives. Among other things, we show that if the threshold
to award a prize is set too low, prizes can result in even lower quality innovation than would
occur in their absence.
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Finally, we model a novel approach to patents – a value-based patent system, where more
socially-valuable inventions receive heightened patent protection (e.g., longer patent duration)
as compared to less socially-valuable ones. We show how a value-based patent system generates
higher-quality innovation than the status quo, while not inadvertently incentivizing low-value
innovation, as would occur with across-the-board increases in patent protection. We close with
a few suggestions on how a value-based patent system might be implemented in practice, refer-
encing other research we are conducting contemporaneously.
2 Prior Literature and Empirical Motivation
Several scholars have recognized problems with marginal or me-too innovation in pharmaceuti-
cals. Jayadev and Stiglitz [2009] claim superior innovative drugs can become unprofitable when
drug companies use better marketing on inferior me-too products. Fojo et al. [2014] similarly
argue that follow-on products can crowd out innovation on new therapeutic targets.1
Me-too drugs are not rare. Régnier [2013] notes that of the 431 new molecular entities
approved by the U.S. Food and Drug Administration (FDA) between 1990 and 2004, 58% had
“therapeutic qualities similar to those of one or more already marketed.” Similarly, Fojo et al.
[2014] observe that out of 71 drugs approved by the FDA between 2002 and 2014 for solid
tumors, “the median gains in progression-free and overall survival (OS) were a very modest
2.5 and 2.1 months, respectively.” And under standards suggested by the American Society
of Clinical Oncology (ASCO) Cancer Research Committee, only 42% of these 71 drugs would
constitute “clinically meaningful improvements.”
Worse, most marginal drugs are not cheap. Figure 1 illustrates the underlying problem.
It summarizes the results for all completed Phase 3 interventional clinical trials with statisti-
cally significant results for treatment of metastatic colorectal cancer (mCRC), as reported at
www.clinicaltrials.gov. The x-axis shows the diﬀerence in median overall survival times for
treatment groups as compared to control groups, averaged across all trials for each drug. The
y-axis lists the annual cost of treatment for each drug, estimated using data collected from
1In contrast, DiMasi and Paquette [2005] suggest most follow-on drugs are developed at the same time as
pioneering drugs. They claim such drugs are not harmful and actually increase therapeutic choice.
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goodRx.com, an online retailer of prescription medication. Averaging across these studies, each
additional month of overall survival costs about $56,000 per year of treatment (and most mCRC
patients undergo multiple years of treatment). Certainly an individual might value one addi-
tional month of life at $56,000 or more. But from a social welfare standpoint, this value greatly
exceeds any reasonable estimate of the average value of an additional month of human life,
especially given the relatively low quality of life for patients with mCRC. See, e.g., Lee et al.
[2009] (estimating the value of a quality-adjusted year of life for patients on dialysis to be about
$129,000). The price charged does not come close to the value delivered.2
Figure 1: Metastatic Colorectal Cancer Drugs: Increments in Average Overall Survival v. Cost
Sources: Overall survival data from clinicaltrials.gov. Cost data estimated using prices on
goodRx.com as of September 2016.
2Some might wonder if the small diﬀerence in median outcomes obscures larger benefits that the treatment
might bestow on certain subpopulations. While this might be possible, it is not reflected in the clinical trial
data. Rather, when one examines Kaplan-Meier curves, which allow one to compare how survival rates vary on
a patent-by-patient basis between treatment and control groups, it is clear the two groups remain relatively close
in terms of overall performance throughout the duration of these studies.
5
Why is there this disconnect between the value delivered by pharmaceutical innovation
and the prices charged by innovators? In related work, Sukhatme and Bloche [2018] explore
this phenomenon, highlighting the impact of moral hazard in health insurance markets, a single-
minded focus of regulators and market participants on statistical versus therapeutic significance,
and drug makers’ marketing strategies for follow-on drugs. Most importantly, they highlight the
psychological and political economy factors that make it diﬃcult for payers and regulators to
limit access to technologies that marginally improve outcomes at tremendous cost. Specifically.
once a new medical technology becomes available, a tangle of human psychology, cultural mores,
clinical ethics and stakeholder expectations makes it diﬃcult for payers and regulators to refuse
to pay for such treatment, even if its cost greatly exceeds the benefits it provides. So firms can
earn large private benefits for new medical technologies that improve upon existing treatments,
however barely. Since path-breaking, high-value technologies are often riskier to pursue than
marginally beneficial technologies, firms are skewed toward pursuing inventions that are less
socially valuable. Put diﬀerently, the various distortions in pharmaceutical markets that allow
firms to earn outsized private benefits for marginal technologies also induce those firms to
produce such technologies rather than riskier, more socially-valuable therapies.
While other scholars do not appear to have tackled this particular question, they have
modeled somewhat related phenomena. Most notably, Ganuza et al. [2009] model how price-
inelastic doctors, who make drug purchase decisions on behalf of insured patients, induce firms
to invest in follow-on innovations instead of pioneering drugs and encourage them to spend on
persuasive as compared to informative marketing to increase demand for me-too drugs. Focusing
on diseases such as HIV/AIDS, Leoni and Sandroni [2016] model how excessive patent duration
can encourage firms to collude with one another to produce marginal innovations rather than
full cures. González et al. [2016] generate a model of follow-on drugs with patients that are
horizontally and vertically diﬀerentiated, and intermediate doctors that act as perfect agents for
the health care system. Antoñanzas et al. [2011] model a game in which pharmaceutical firms
launch product line extensions after their drug patents expire, with “loyal” doctors prescribing
the product line extension and “non-loyal” ones taking into account drug prices. Finally, Bardey
et al. [2010] model a dynamic game with firms, consumers, and regulatory agencies to measure
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how reference pricing – which involves categorizing drugs by class and determining a common
price for that class – can change firms’ dynamic innovation incentives and reduce health.
Our paper builds on this previous literature by adding a new dimension: the risk/return
tradeoﬀ that technology firms face when deciding which investment project to pursue. For
pharmaceuticals, the choice is often between pursuing a follow-on innovation (which might focus
on a known molecular target that has already been successfully targeted by an existing drug)
or pursuing a potentially more beneficial but riskier original innovation. Our model formalizes
and explores the consequences of what recent empirical research by Krieger et al. [2018] shows:
that pharmaceutical companies view incremental innovation as less valuable but much less risky
than more novel, potentially path-breaking innovations.
While we have not found other models of such decisionmaking, other scholars have looked
more generally at how risk and return influence firms’ investment decisions. Notably, Rose-
Ackerman [1991] explored how the risk of bankruptcy can cause firm decisionmakers to sacrifice
expected returns for lower risk.
3 Discrete Choice Model
3.1 Monopolistic environment
We begin with a simple discrete choice model to illustrate why firms might pursue socially-
suboptimal innovation. A risk-neutral representative firm seeks to create a new innovation in a
particular field.3 In this monopolistic environment, we assume the inventor owns a patent on
the new technology and hence has a legal monopoly over its production.
Let X be the realized net social value of the new technology. In other words, it is the
value of the new technology to a social planner.4 Each technology has a threshold, X, and
any technologies whose social value X < X are normalized and assumed to be worth 0 for the
inventor. For simplicity, we assume that technologies with X < X have no social value either,
3In the pharmaceutical context, one can view the underlying field as a particular drug indication (e.g., first-line
treatment for metastatic colorectal cancer).
4All private and social values referenced here can either be in aggregate or per capita terms; the intuition of
the model remains the same either way.
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though our results remain the same if we assume the social planner receives some value x for
these inventions.
In some markets, X might be interpreted as the most advanced technology that exists,
or the “state of the art.” In other markets, one can think of X as the threshold below which
a technology provides the firm with no profits. For pharmaceuticals, the latter interpretation
might be more appropriate, where X is the baseline safety/eﬃcacy profile below which the FDA
will not approve a drug, and hence the drug generates no private value.
The returns the inventor receives are not necessarily the same as the social planner. Let
m (X) be the inventor’s profit as a function of the social value of the new technology. Suppose
m (X) takes the following piecewise linear form:
m (X) =
8>><>>:
0 for X < X
X + b, for X   X
, in which b   0
The value b is the guaranteed fixed private return the inventor receives if his technology
meets or exceeds the thresholdX. In the context of pharmaceuticals, b is the private benefit firms
receive for producing drugs that barely improve over existing therapies (Sukhatme and Bloche
[2018]). In other contexts, b might be the private cost of producing a new product inferior to the
current state of the art, such as private costs incurred on firm managers and board members if a
product fails and the firm goes bankrupt. When b = 0, there is no distortion and the inventor’s
profit function is the same as the social planner; hence the inventor will choose socially-optimal
projects.
The realized social value of each potential technology the inventor could select is uncertain.
It is represented by a binomial distribution in which with probability p the technology achieves
X¯ > X and with probability 1   p it falls below X. Assume there are only two choices for
the inventor: a risky project summarized by
 
pH , X¯H
 
and a safe one
 
pL, X¯L
 
in which X¯H >
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X¯L > X and 0 < pH < pL < 1. Suppose further that pHX¯H > pLX¯L, which implies choosing
the risky project is socially optimal.5
The inventor will pick the project with higher expected private return. Therefore, he will
pick the safe project iﬀ:
(1  pL) ⇤ 0 + pLm
 
X¯L
 
> (1  pH) ⇤ 0 + pHm
 
X¯H
 
() pL
 
X¯L + b
 
> pH
 
X¯H + b
 
() b > pHX¯H   pLX¯L
pL   pH ⌘ bM > 0 (1)
If the distortion b exceeds the threshold bM , the inventor will pursue the less risky, socially-
suboptimal project. Intuitively, this is because the profit diﬀerential between high- and low-value
inventions is not as large for the inventor as it is for the social planner. While an inventor still
receives a higher return if she picks a risky project and the resulting value exceeds X, she has
to trade oﬀ that increase in return with the heightened risk of falling below X and earning
nothing. Unlike the social planner, the inventor obtains a fixed benefit b from any innovation
that improves on the status quo, however marginally. Since the inventor receives this “boost”
unconditionally for any invention whose social value exceeds X, and higher-value inventions are
riskier, the inventor might choose a less risky project than the social planner.
3.2 Competitive environment
Next we introduce competition into the environment. First, assume there are two identical
firms that seek to create new innovations in a particular field, with both firms having the same
return function m(X) as before. Both are entitled to produce the underlying technology (i.e.,
neither can exclude the other from production via a patent). Again we assume there are only
two choices for the firms, a risky project
 
pH , X¯H
 
and a safe one
 
pL, X¯L
 
. We have three
cases (due to firms being identical), with the corresponding return matrices specified below:
5Here we make the standard assumption that a social planner is risk-neutral and seeks to maximize expected
value. We recognize our analysis might yield a diﬀerent result under other less common approaches, such as
those used in regret theory models in which policymakers choose policies that minimize maximum regret.
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Case 1. Both firms pick the safe projects:
< X X¯L
< X 0, 0 X¯L + b, 0
X¯L 0, X¯L + b
X¯L
2 + b,
X¯L
2 + b
Case 2. Both firms pick the risky projects:
< X X¯H
< X 0, 0 X¯H + b, 0
X¯H 0, X¯H + b
X¯H
2 + b,
X¯H
2 + b
Case 3. One firm picks the risky and the other firm picks the safe project:
< X X¯L
< X 0, 0 X¯L + b, 0
X¯H 0, X¯H + b X¯H + b, 0
In other words, the two firms split X¯L (X¯H) if they both pick the low-value (high-value) project
and both are successful, and a firm receives nothing if its competitor achieves a higher-value
outcome than it does.
Note that in our model, b is not whittled down by competition. This is a key assumption
that reflects our underlying view of b – it is a private return that firms receive that is inde-
pendent of the value they deliver, so long as their product exceeds the technology threshold X.
Whether viewed as being driven by patient psychology and political economy (Sukhatme and
Bloche [2018]) or private costs borne by firm managers if a project fails (Rose-Ackerman [1991]),
competition does not diminish b here. Our approach is supported by some empirical evidence in
the pharmaceutical context, which suggests that introduction of new me-drugs might not lower
other related drugs’ prices. See Figure 1; also compare Ekelund and Persson [2003] (introduc-
tion of branded substitutes has little eﬀect on introductory price or price dynamics in Swedish
market) with Lu and Comanor [1998] (more branded substitutes in U.S. market lead to lower
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introductory prices and lower subsequent price increases). At any rate, even if b is reduced in
the real world by competition, the distortion we identify here is possible so long as b remains
suﬃciently large, as discussed below.
We look for the condition in which both firms will pick the socially-suboptimal, safe project
in a Nash equilibrium. Conditioning on the other firm picking the safe project, the expected
return for a firm if it also picks the safe project is:
p2L
✓
X¯L
2
+ b
◆
+ (1  pL) pL
 
X¯L + b
 
= pL

X¯L
2
pL + (1  pL) X¯L + b
 
If it picks the risky project, the expected return will be:
pH
 
X¯H + b
 
Therefore, the best response for the firm will be the safe project iﬀ:
pL

X¯L
2
pL + (1  pL) X¯L + b
 
> pH
 
X¯H + b
 
() b >
pHX¯H   pL
h
X¯L
2 pL + (1  pL) X¯L
i
pL   pH ⌘ bO (2)
Notice that bO > bM , which means adding in a competitor raises the threshold over which
a high b will result in a distortion. Still, duopoly only mitigates, and does not eliminate, the
potential problem. If the private distortion b is large enough, both firms will still choose the
socially-suboptimal project.
More generally, we can expand our analysis to n identical competing firms. If n  1 firms
choose the low-value project, the remaining firm will also choose the low-value project if the
expected return from doing so exceeds the expected return from choosing the high-value project:
pL
n 1X
k=0
✓✓
n  1
k
◆
pkL (1  pL)(n 1 k)
◆✓
X¯L
k + 1
+ b
◆
> pH
 
X¯H + b
 
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Multiplying out the left-hand side, we can simplify the first term on that side as follows:
pLX¯L
n 1X
k=0
✓
(n  1)!
k!(n  1  k)!p
k
L (1  pL)(n 1 k)
1
k + 1
◆
=
✓
pLX¯L
n
◆ n 1X
k=0
✓
n!
(k + 1)! (n  (k + 1))!p
k
L (1  pL)(n 1 k)
◆
=
✓
pLX¯L
n
◆ nX
j=1
✓
n!
j! (n  j)!p
j 1
L (1  pL)(n j)
◆
=
✓
X¯L
n
◆0@ nX
j=0
✓✓
n
j
◆
pjL (1  pL)(n j)
◆
  (1  pL)n
1A
=
✓
X¯L
n
◆
(1  (1  pL)n)
And so the whole equation simplifies to the following condition:
b >
pHX¯H   [1  (1  pL)n] X¯Ln
pL   pH ⌘ bn (3)
As n!1, the second term in the numerator goes to 0, and so:
b >
pHX¯H
pL   pH ⌘ bC
Accordingly, even in a perfectly competitive market, if the private distortion b exceeds the
threshold bC , all firms in the market will still choose the socially-suboptimal project. So no
amount of competition guarantees that firms will choose the social optimum.
3.3 New entrants
Finally, we consider an environment in which a monopolistic incumbent seeks to create a new
innovation while simultaneously facing the threat of competition from a potential entrant. The
entrant chooses between: no entry, entry and pick the safe project, or entry and pick the risky
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project. The entry cost is c > 0. Assume further that pHX¯H > c, or the expected social value
of the risky project is higher than the entry cost. The return matrix of the game is:
Risky Safe
No entry pH
 
X¯H + b
 
, 0 pL
 
X¯L + b
 
, 0
Entry & Risky p2H
⇣
X¯H
2 + b
⌘
+
pH (1  pH)
 
X¯H + b
 
, pL (1  pH)
 
X¯L + b
 
,
p2H
⇣
X¯H
2 + b
⌘
+ pH
 
X¯H + b
   c
pH (1  pH)
 
X¯H + b
   c
Entry & Safe p2L
⇣
X¯L
2 + b
⌘
+
pH
 
X¯H + b
 
, pL (1  pL)
 
X¯L + b
 
,
pL (1  pH)
 
X¯L + b
   c p2L ⇣ X¯L2 + b⌘+
pL (1  pL)
 
X¯L + b
   c
The Nash equilibrium of this game will be (Safe, Entry & Safe) if b > bO. So if the
distortion exceeds the threshold bO, both the entrant and the incumbent will pick the suboptimal
safe choice, as was the case in the duopolistic environment.
4 Continuous Choice Model
Now we generalize the previous model into one in which a firm can choose from a continuous set
of potential R&D projects, with continuous returns. As before, X is the social value of the new
technology with a technology threshold, X, below which the technology has zero private value.
The planner always receives return X from the invention, whether it exceeds the technology
threshold X or not.
The inventor’s profit function m (X) now takes the following piecewise linear form:
m (X) =
8>><>>:
0 for X < X
mX + b, for X   X, 0 < m  1, b   0
As before, b is the guaranteed fixed private return the inventor receives if her technology
meets or exceeds the technology threshold X. m is the return factor the inventor receives
depending on how much her invention’s social value exceeds this threshold.
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Once again, the inventor knows his profit function but not the realized outcome.6 The social
value of each potential technology the inventor could select is represented by a distribution
G
 
X;µ, 2
 
over its social return. Assume that within the inventor’s choice set, G is fully
identified by its mean µ and variance  2 and that G
 
X;µ, 2
 
is fully diﬀerentiable with respect
to µ and  2.
Furthermore, as µ increases, so does  2. That is  2   h (µ), where h0 (µ)   0, so social
value and risk increase together.
Proposition 4.1. (The planner’s solution) The planner chooses the project with the highest
mean µ. He is indiﬀerent with respect to variance  2.
Proof. This follows immediately from the planner’s risk-neutrality; he does not care about the
variance of the distribution G (X) and only picks projects with the highest mean µ, since his
return is just X.
By contrast, the inventor chooses a technology with mean µ and variance  2 that maximizes
her expected return E (m (X)). This can be written as the following optimization problem:
max
µ, 2
E
⇥
m (X) |µ, 2⇤
s.t.
 2   h (µ)
To begin, consider the scenario in which the inventor picks the lowest variance project for
a given µ. In other words, the constraint in the optimization problem binds and  2 = h (µ).
The optimization problem then becomes:
6We could easily add uncertainty to the inventor’s knowledge of her profit function by adding some symmetrical
noise (e.g., ✏ ⇠ N(0, 2✏ ) ) to the value of m. But this would not change the results here since the inventor is an
expected utility maximizer, m only enters the optimization problem linearly, and E(m+ ✏) = m.
14
max
µ
E [m (X) |µ, h (µ)]
= max
µ
Z
X
(mx+ b) dG (x;µ, h (µ))
() max
µ
Z
X
✓
x+
b
m
◆
dG (x;µ, h (µ))
= max
µ
✓
X +
b
m
◆
[1 G (X;µ, h (µ))] +
Z 1
X
(x X) dG (x;µ, h (µ))
First-order condition (FOC):
d
dµ
E [m (X) |µ, h (µ)]
=
✓
X +
b
m
◆
d
dµ
[1 G (X;µ, h (µ))] + d
dµ
Z 1
X
(x X) dG (x;µ, h (µ))
=  
✓
X +
b
m
◆
G2 (X;µ, h (µ))h
0 (µ) 
✓
X +
b
m
◆
G1 (X;µ, h (µ))
+
d
dµ
Z 1
X
(x X) dG (x;µ, h (µ))
As µ increases, both µ and h (µ) go up. The first term in FOC,
   X + bm G2 (X;µ, h (µ))h0 (µ), is the partial eﬀect of an increase in variance h (µ) on
G (X;µ, h (µ)). It reflects the chance of falling below the threshold X.
The second term    X + bm G1 (X;µ, h (µ)) is the partial benefit of higher µ on
G (X;µ, h (µ)). Since increasing µ while keeping  2 constant is equivalent to a first-order
stochastic dominant shift, it reduces the chance of falling below the threshold X. Thus,
G1 (X;µ, h (µ))  0 and  
 
X + bm
 
G1 (X;µ, h (µ))   0.
The third term ddµ
R1
X (x X) dG (x;µ, h (µ)) > 0 measures the benefit of a higher µ on
the added reward of obtaining an invention above the threshold, which is an increasing function
of µ.
We can see, therefore, that a suﬃcient condition for the firm to pick a lower µ than the
social planner is:
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Condition 1.
✓
X +
b
m
◆
G2 (X;µ, h (µ))h
0 (µ)  
 
✓
X +
b
m
◆
G1 (X;µ, h (µ)) +
d
dµ
Z 1
X
(x X) dG (x;µ, h (µ))
Proposition 4.2. If the inventor picks the lowest variance project  2 for a given µ, and Con-
dition 1 is satisfied, then the inventor chooses µM that is strictly lower than that picked by the
planner, µS.
Proof. Follows directly from the discussion above.
Note that Condition 1 can also be written in terms of h0 (µ):
h0 (µ)  
   X + bm G1 (X;µ, h (µ)) + ddµ R1X (x X) dG (x;µ, h (µ)) 
X + bm
 
G2 (X;µ, h (µ))
Written this way, it becomes clear that Condition 1 essentially requires risk to increase
with return steeply enough such that it exceeds a certain threshold. Then, the inventor will
choose a socially-suboptimal project.
We now make the following assumption:
Assumption 1. (Diminishing return to risk) @
2
@( 2)2
E
⇥
m (X) |µ, 2⇤  0
Assumption 1 requires the return to taking more risks at a given level of µ is decreasing
with  2. This assumption reflects the reality that there are diminishing gains from taking on
more risk for a distribution with a given µ.
With Assumption 1 in place, we can now show the following:
Proposition 4.3. If Condition 1 and Assumption 1 hold, then the inventor will pick the lowest
 2 for any given µ, as well as a socially-suboptimal project. That is, the constraint  2   h (µ)
will bind, and the inventor’s choice µM < µS.
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Proof. By Assumption 1, @@ 2E
⇥
m (X) |µ, 2⇤ is non-increasing w.r.t  2. Therefore, if
@
@ 2E [m (X) |µ, h (µ)]  0 , then @@ 2E
⇥
m (X) |µ, 2⇤  0 for all  2   h (µ). Since Condi-
tion 1 implies
d
dµ
E [m (X) |µ, h (µ)]  0
() @
@ 2
E [m (X) |µ, h (µ)]h0 (µ) + @
@µ
E [m (X) |µ, h (µ)]  0
Because @@µE [m (X) |µ, h (µ)]   0, since it is equivalent to a first-order stochastic dominant
shift, and h0 (µ)   0 by assumption, we must have @@ 2E [m (X) |µ, h (µ)]  0.
In other words, Condition 1 and Assumption 1 together ensure that the inventor will pick
a project with minimum variance  2 for a given mean µ, and that the project she picks will
have a lower mean µM than what the social planner would pick µS .
5 Policy Interventions
We have shown that even a risk-neutral inventor will pursue a suboptimal technology if the
tradeoﬀ between risk and return rises steeply enough.7 We now explore the comparative statics
of our model. We then discuss four possible policy interventions: an increase in the technology
threshold, a reward for high-value inventions, a tax that disparately penalizes low-value inven-
tions combined with a subsidy that insures against project failure, and a value-based patent
system. We also examine how mismeasurement of model parameters by a policymaker might
aﬀect policy decisions.
5.1 Comparative Statics
In this section, Condition 1 and Assumption 1 are assumed to hold throughout. In terms of
our model, we can see how changes to m, b, and X change the inventor’s choice by deriving the
following comparative static results for these parameters.
7Note that throughout this discussion we have not relied on any sort of risk-aversion. Adding that to the
analysis would only make the risk/return tradeoﬀ more stark for the inventor, increasing the wedge between the
social planner and the inventor.
17
Proposition 5.1. The inventor’s choice of µ is increasing in m.
Proof. Recall the FOC:
 
✓
X +
b
m
◆
G2 (X;µ, h (µ))h
0 (µ) 
✓
X +
b
m
◆
G1 (X;µ, h (µ)) +
d
dµ
Z 1
X
(x X) dG (x;µ, h (µ))
Diﬀerentiating the FOC w.r.t m gives us:
b
m2
[G2 (X;µ, h (µ))h
0 (µ) +G1 (X;µ, h (µ))] (4)
From Condition 1, we have:
G2 (X;µ, h (µ))h
0 (µ) +G1 (X;µ, h (µ))  
d
dµ
R1
X (x X) dG (x;µ, h (µ)) 
X + bm
 
We know the right hand side term > 0 , which implies quantity 4 > 0.
Intuitively, as m increases, the inventor receives more profit than before for each additional
unit of social value that she generates. As such, the inventor has greater incentive to produce
higher social value inventions.
Put diﬀerently, one can view m  1 as the proportion of the total welfare generated by
the sale of the product that the firm receives. As m! 1, the firm gains more of the total social
welfare and consumer surplus goes to 0.
Proposition 5.2. The inventor’s choice of µ is decreasing in b.
Proof. Diﬀerentiating the FOC w.r.t b gives us:
  1
m
[G2 (X;µ, h (µ))h
0 (µ) +G1 (X;µ, h (µ))] (5)
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From Condition 1, we have:
G2 (X;µ, h (µ))h
0 (µ) +G1 (X;µ, h (µ))  
d
dµ
R1
X (x X) dG (x;µ, h (µ)) 
X + bm
 
We know the right hand side term > 0 , which means quantity 5 < 0.
As b decreases, the inventor’s guaranteed private “boost” from generating any passable
invention (i.e., any invention whose social value exceeds X) decreases. This disparately aﬀects
lower-value inventions, since both high- and low-value inventions receive the same boost. As
such, the private value of high-value inventions relative to low-value ones increases, and the net
marginal benefit from increasing µM goes up.
What if X (i.e., the technology threshold) increases? Diﬀerentiating FOC w.r.t X, we
have:
d
dX

d
dµ
E [m (X) |µ, h (µ)]
 
= m
d
dX

d
dµ
Z 1
X
✓
x+
b
m
◆
dG (x;µ, h (µ))
 
= m
d
dµ

d
dX
Z 1
X
✓
x+
b
m
◆
dG (x;µ, h (µ))
 
=
d
dµ
(mX + b) g (X;µ, h (µ))
= (mX + b)
d
dµ
g (X;µ, h (µ)) (6)
where g (.) the pdf of distribution G. We know that (mX + b) > 0. So the eﬀect of
increasing X depends on the sign of ddµg (X;µ, h (µ)).
Proposition 5.3. If ddµg (X;µ, h (µ))  0 then the inventor’s choice of µ will be decreasing in
X, and the inventor is more likely to pick a socially-suboptimal innovation as X increases. If
d
dµg (X;µ, h (µ)) > 0 then the inventor’s choice of µ will be increasing in X, and the inventor
is less likely to pick a socially-suboptimal innovation as X increases.
Proof. If ddµg (X;µ, h (µ))  0, then Condition 1 is more likely to hold as X increases. If
d
dµg (X;µ, h (µ)) > 0, then Condition 1 is less likely to hold as X increases.
So what is the likely sign of ddµg (X;µ, h (µ))? This will of course depend on the underlying
distribution G. But for many common classes of distributions, the sign is likely to be negative.
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For example, consider the class of exponential distributions. In that case:
g (X;µ, h (µ)) ⌘ 1
µ
e 
X
µ
=) d
dµ
g (X;µ, h (µ)) =   1
µ2
e 
X
µ +
1
µ
X
µ2
e 
X
µ =
e 
X
µ
µ3
(X   µ) (7)
It is likely that an inventor will pick a project whose expected return µ exceeds the status
quo, X. As such, quantity (7) will be negative and increasing X will make it more likely that
Condition 1 holds, thereby increasing the chances an inventor will pick a socially-suboptimal
project.
As another example, consider the class of normal distributions:
g (X;µ, h (µ)) =
 
1p
2⇡h (µ)
!
e
 
✓
(X µ)2
2h(µ)
◆
=) d
dµ
g (X;µ, h (µ)) = 
1p
2⇡h (µ)
!
⇤ e 
✓
(X µ)2
2h(µ)
◆
⇤
✓
(X   µ)
 1
2h
0 (µ) (X   µ) + h (µ)
h2 (µ)
 ◆
+e
 
✓
(X µ)2
2h(µ)
◆
⇤
 
  ⇡h
0 (µ)
(2⇡h (µ))3/2
!
= e
 
✓
(X µ)2
2h(µ)
◆ h
(2⇡h (µ)) 1/2
i "
(X   µ)
✓
1
h (µ)
◆
+
h0 (µ)
2h (µ)
"
(X   µ)2
h (µ)
  1
##
(8)
This implies that ddµg (X;µ, h (µ)) < 0 if h (µ) > (X   µ)2 (i.e., the variance at a given µ
increases quickly enough) and X  µ < 0 (i.e., the expected return µ exceeds the status quo, X,
as is likely). In that case, quantity (8) will be negative. So once again, increasing X will make
it more likely that Condition 1 holds, thereby increasing the chances of a socially-suboptimal
choice by an inventor.
20
5.2 Increase in Technology Threshold
We can now explore various policy interventions to align the inventor’s incentives with those of
the social planner. We begin with a straightforward intervention: an increase in the technology
threshold X.
In some settings, this threshold may depend solely on factors outside a policymaker’s
control. In the context of pharmaceuticals, however, the FDA may exert considerable control
over this level. In particular, drugs whose clinical safety and eﬃcacy profile falls below X are
not approved and provide zero private returns. Still, while the FDA might be able to increase
X, the existing state of technology in a given field likely sets a floor for this value, because it
is unlikely that pharmaceutical companies could obtain significant returns on new drugs that
actually perform worse than ones that already exist.
Based on Proposition 5.3 and the discussion in the previous section, we can see it is possible
that increasing the technology threshold will increase the chances that an inventor pursues a
lower value innovation than the social planner would pursue. The underlying reason is clear:
increasing the technology threshold increases the risk that an inventor will obtain zero returns
for a given project. As such, even a risk-neutral inventor will pursue a less risky project in such
a scenario, if risk increases sharply enough with return. Accordingly, what might seem to be a
simple solution – increasing the regulatory technology threshold X to deter me-too products -
may paradoxically cause firms to take on less risk and pursue more me-too innovation.
A corollary of this result is that the problem of suboptimal innovation in a given field
might increase as the field advances over time. This is because X will continue to increase,
and inventors will become more prone to pursuing less risky, socially-suboptimal innovations to
reduce their chance of obtaining zero returns.
5.3 Rewards and Taxes
Next we derive the following results for a reward or prize system in which the inventor receives
a prize P > 0 if the social value of the invention exceeds some threshold k. The optimization
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problem now becomes:
max
µ, 2
E
⇥
m (X) |µ, 2, P ⇤
= max
µ, 2
Z
X
(mx+ b) dG
 
x;µ, 2
 
+ P
 
1 G  k;µ, 2   
() max
µ, 2
Z
X
✓
x+
b
m
◆
dG
 
x;µ, 2
 
+
P
m
 
1 G  k;µ, 2   
Assumption 2. (Diminishing return to risk) @
2
@( 2)2
E
⇥
m (X) |µ, 2, P ⇤  0
Assumption 2 is analogous to Assumption 1; it requires the return to taking more risks at
a given level of µ be decreasing with  2 even with the prize system. Similar to the discussion in
Section 4, the suﬃcient condition for the inventor to pick a suboptimal project now becomes:
Condition 2.
✓
X +
b
m
◆
G2 (X;µ, h (µ))h
0 (µ) +
P
m
G2 (k;µ, h (µ))  
 
✓
X +
b
m
◆
G1 (X;µ, h (µ))  P
m
G1 (k;µ, h (µ))
Remark 5.1. When k = X, any reward P > 0, is equivalent to an increase in b. Thus, such a
reward incentivizes the inventor to pick a lower mean project µP < µM .
More generally, a prize that is awarded for crossing too low of a threshold could be coun-
terproductive: it might encourage that inventor to actually produce a lower-value invention.
Is there a situation under which the reward system helps mitigate the problem? Since
  PmG1 (k;µ, h (µ)) > 0, Condition 2 will be less likely to be satisfied if G2 (k;µ, h (µ)) < 0.
Proposition 5.4. Suppose the inventor, whose status quo choice is µM , receives a prize P > 0
if the social value of the invention exceeds some threshold k. If his expected return exhibits
diminishing return to risk (Assumption 2) and Condition 2 holds, then the inventor’s choice µP
is suboptimal. Furthermore, if G2 (k;µ, h (µ)) < 0, he will select a project with µP > µM .
Proof. Follows from the discussion above.
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We can see what is the minimal level at which a prize will improve inventor incentives for
the class of normal distributions. In that case:
G (k;µ, h (µ)) =
1
2
"
1 + erf
 
k   µp
2h (µ)
!#
=) G2 (k;µ, h (µ)) = 1
2
2p
⇡
e
 
✓
k µp
2h(µ)
◆2
k   µp
2
 1
2
h (µ) 
3
2
=   1
2
p
2⇡
e
 
✓
k µp
2h(µ)
◆2
k   µp
2
h (µ) 
3
2
Therefore, G2 (k;µ, h (µ)) < 0 if k > µ. Again, the intuition here is straightforward: if a
prize or reward is provided for inventions whose social value exceeds a suﬃciently high threshold
(i.e., k   µ), then the inventor will select an investment project with higher unconditional
expected social returns than in the absence of a prize.
Given that low-end rewards are problematic, a lump-sum tax might reduce the gap between
the inventor and the social planner. In fact, we can easily derive the following result:
Corollary 5.1. If Condition 1 and Assumption 1 hold, an inventor-specific lump sum tax
of ⌧ = b placed on all innovation that exceeds the technology threshold X will help align the
inventor’s incentives with those of the social planner.
Proof. Such a tax is identical to a corresponding reduction in b. Note that this disproportionately
aﬀects lower-value inventions that exceed the technology threshold X.
Corollary 5.2. If Condition 1 and Assumption 1 hold, a subsidy s = X for innovations lower
than the technology threshold X and s = (1 m)X for innovations higher than X together
with a inventor-specific lump sum tax will fully align the inventor’s incentives with those of the
planner.
Proof. The combination of the subsidy and the tax will align the inventor’s return function with
that of the social planner.
The subsidy belowX acts as insurance for projects that fall below the technology threshold,
thereby encouraging the inventor to take on more risk. The subsidy above X acts like a value-
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based patent system, discussed in more detail below. In particular, since m  1, this operates
as a subsidy that disparately benefits higher-value inventions.8
5.4 Value-Based Patent Protection
Finally, what about changes to the patent system? Patents give inventors a legal monopoly over
their inventions, enabling them to exclude others from making, using, selling, oﬀering to sell,
or importing their inventions into a country for a limited period of time. Whether this legal
monopoly translates into an economic monopoly depends on market demand. All else being
equal, we would expect a patent on a product that generates more social value to generate
higher profits. That relationship is captured by the profit function in our model, with m > 0.
Ideally, we want a system where the increased benefit to the inventor is proportional to
the social value of the invention. This sort of value-based patent system would boost profits
for inventions with higher social value as compared to those that have lower social value. As a
practical matter, this might be implemented by adjusting patent duration based on the social
value of the underlying invention. In terms of our model, we can think about the eﬀect of
increased patent protection as an strict increase in the slope parameter m.
Proposition 5.5. Suppose the inventor receives an increase in patent protection proportional
to the invention’s underlying social value, which is equivalent to an increase from m to m0 > m.
Under Assumption 1, the inventor will pick µ0M > µM .
Proof. This follows directly from Proposition 5.1.
Note that, if in addition to increasing m, we decrease patent protection for low-value
inventions, that would be equivalent to lowering b. From Proposition 5.2 above, we can see this
would also increase an inventor’s choice of µ.
Instead of a value-based patent system, why not more just increase patent protection
uniformly across the board, regardless of the social value of the invention? Such a increase would
provide a boost to all products that generate positive profits for a firm (i.e., where X > X). In
8By contrast, one can see that a proportional tax – one that takes a fixed percentage of pharmaceutical profits
– might exacerbate firms’ tendency to pick low-value inventions. This follows directly from Proposition 5.1, since
a proportional tax in eﬀect reduces the slope m of the inventor’s profit function.
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our model, this would be roughly modeled as an increase in the intercept parameter, b. But as
we have seen, such a boost would actually increase the gap between the inventor’s and social
planner’s incentives. To the extent we want to minimize deviations from the status quo, such
a policy would be suboptimal, because we would need to increase the slope parameter m even
more to counteract the eﬀect of raising b at the same time.
5.5 Policy under Incomplete Information
Throughout this paper, we have assumed the policymaker has the same complete information
as the representative firm. But if the firm has private unobservable information in its invest-
ment choice set, then the policymaker may have a biased estimate of model parameters, which
could lead to wasteful policy interventions such as unnecessary or excessive rewards to induce
innovation.
To illustrate, consider a reward intervention in the monopoly discrete choice model as
discussed in Section 3.1 above. Let the social cost of raising money for the reward be a continuous
function S(r), where S0(r)   0. This social cost may be, for example, the deadweight loss caused
by taxation used to raise revenues to pay the reward. Assume as before pHX¯H pLX¯L > 0. The
social planner does not know pH but has an estimate pˆH . It knows the other model parameters
X¯H , pL, X¯L, X, b.
Proposition 5.6. The only situation in which a reward system might be worse than the status
quo is if the social planner underestimates pH .
Proof. In Appendix.
In the worst-case situation, the firm is already picking the higher-value project, and the
planner incorrectly perceives the firm as picking the lower-value project. Accordingly, the plan-
ner would oﬀer a windfall, or a reward that was unnecessary to induce the higher-value choice.
For other model parameters, X¯H , pL, X¯L, b,9 similar logic applies. In particular, a reward
system might be worse than the status quo only if the social planner underestimates X¯H or
9We assumeX always yields zero payoﬀs; this can be viewed as a normalization and hence any mismeasurement
of X is captured by mismeasurement of X¯H and X¯L.
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overestimates pL, X¯L, or b. In these scenarios, the firm would receive a windfall, since it would
have chosen the high-value project even if no reward had been provided.
The potential for mismeasurement identified here is unlikely to lead to outcomes worse
than the status quo. If anything, we might worry about overly optimistic social planners who
overestimate pH and/or X¯ (i.e., they believe the chances of success or the value of the high-
value project are greater than they actually are) or underestimate pL and/or X¯L (i.e., they
believe the chances of success and value of the lower-value project are less than they actually
are). These measurement errors would, at worst, lead to the status quo. While overestimates
of b might cause policymakers to provide windfall payments to firms, this parameter is actually
quite measurable – for example, as discussed in the context of metastatic colorectal cancer
drugs, we can estimate b by measuring price markups for new drugs that marginally improve
over inexpensive treatments like chemotherapy. As such, mismeasurement probably should not
be a significant concern for policymakers and should not deter them from implementing the
policy interventions proposed here.
6 Conclusion
Our paper models how risk and return influence the investments that technology companies
make when investing in new products. In particular, we show if firms obtain a fixed private
benefit from producing new technologies that marginally exceed the state of the art, firms will
invest in less risky, socially-suboptimal R&D projects. We further show that competition and
new entrants mitigate but do not eliminate the distortion created by the fixed private benefit.
For pharmaceuticals and biotechnology firms, our model formalizes a motivation for these firms
to “reach for mediocrity” and pursue me-too innovations – less risky projects that add little
social benefit over the status quo.
We also explore various policy interventions that could be used to reduce the gap in in-
centives between inventors and the social planner. We show that an increase in the technology
threshold is ambiguous in this regard, though it may exacerbate the problem we identify here
for common classes of return distributions. By contrast, rewards for high-value inventions and
lump-sum taxes that disparately aﬀect low-value inventions will reduce the potential problem.
26
In addition, we show that a value-based patent system, with increasing patent rents provided
to inventors based on the underlying social value of the invention, could induce inventors to
pursue optimal risk/return tradeoﬀs and innovations that are maximally socially beneficial. We
explain why such a system would be more eﬀective than across the board increases in patent
protection.
Since the wedge between private and social incentives appears to be especially large in
the context of pharmaceuticals, this would be an obvious place where a value-based patent
system could be useful. How might this system be implemented in practice? As we discuss
in our related work (Sukhatme and Bloche [2018]), there are a number of existing metrics of
clinical safety and eﬃcacy that enable us to measure drug value. For instance, quality-added
life years are an increasingly commonly-used metric that measures average increases in lifespan
provided by drugs, discounted by their eﬀect on patients’ quality of life. And in the context of
cancer medication, the American Society of Clinical Oncology has recently suggested value-based
metrics for patients and doctors to consider when choosing therapies (Schnipper et al. [2015]).
Such metrics could be adapted to form the basis of a value-based drug patent system. This
approach would enable significant innovations to receive greater rewards than me-too products,
thereby channeling private resources toward more socially-beneficial outcomes.
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Appendix
A Proof of Proposition 5.6
Proof. It is socially optimal to oﬀer a reward r only within the range 0 < rmin < r  rmax,
where these values are:
rmin = max

pL
pH
 
X¯L + b
    X¯H + b  , 0 
rmax = S
 1
✓
X¯H   pL
pH
X¯L
◆
If rmin > rmax, then the benefit from inducing the higher-value project is less than the
social cost of generating the reward. If rmin  rmax, then the socially-optimal reward is rmin.
Note that if pLpH
 
X¯L + b
     X¯H + b  < 0, the reward is 0 because the firm is already picking
the higher-value project.
Now suppose the planner observes pH with error, such that pˆH < pH . Then the planner’s
perceived (rˆmin, rˆmax) will be:
rˆmin = max

pL
pˆH
 
X¯L + b
    X¯H + b  , 0    rmin
rˆmax = S
 1
✓
X¯H   pL
pˆH
X¯L
◆
< rmax
Note that if rmin > rmax then rˆmin > rˆmax. So the planner will correctly eschew providing
a reward if the social costs of the reward exceed the benefits. If rˆmin > rˆmax but rmin  rmax,
then the planner will not provide a reward even though doing so would be socially optimal, and
the status quo will remain.
Now examine two cases – first, assume the firm picks the lower-value project, so we know
pL
 
X¯L + b
 
> pH
 
X¯H + b
 
and so rmin > 0. The social planner will correctly infer the firm
is picking the lower-value project, since rˆmin   rmin > 0. The planner will oﬀer to pay more
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than the optimal reward rmin, but would not do worse than the status quo, where no reward is
provided.
Next, let pL
 
X¯L + b
 
< pH
 
X¯H + b
 
and so rmin = 0; accordingly, the firm is already
picking the higher-value project. If pL
 
X¯L + b
 
< pˆH
 
X¯H + b
 
, then the planner will still
correctly infer the firm’s choice and will not oﬀer a reward. If pˆH is low enough such that
pL
 
X¯L + b
 
> pˆH
 
X¯H + b
 
, the planner will incorrectly believe the firm is picking the lower-
value project and will oﬀer rˆmin as a reward, so long as rˆmin  rˆmax. This will generate an
unnecessary social cost S (rˆmin).
Now suppose instead pˆH > pH . Then the perceived (rˆmin, rˆmax) will be:
rˆmin = max

pL
pˆH
 
X¯L + b
    X¯H + b  , 0   rmin
rˆmax = S
 1
✓
X¯H   pL
pˆH
X¯L
◆
> rmax
First, assume pL
 
X¯L + b
 
> pH
 
X¯H + b
 
, so the firm chooses the lower-value project. If
pL
 
X¯L + b
 
< pˆH
 
X¯H + b
 
, then the planner will mistakenly believe the firm is already picking
the higher-value project and will keep the status quo. If pL
 
X¯L + b
 
> pˆH
 
X¯H + b
 
, then
the planner will oﬀer to pay the reward rˆmin, so long as rˆmin > 0 and rˆmin  rˆmax. But since
rˆmin < rmin, the reward would be insuﬃcient to induce the firm to pick the higher-value project,
and the status quo will remain.
Now instead suppose pL
 
X¯L + b
 
< pH
 
X¯H + b
 
or rmin = 0, so the firm is already
picking the higher-value project. Since rˆmin  rmin = 0, it must be that rˆmin = 0. The planner
will correctly infer the firm’s choice and will not oﬀer a reward.
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